Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Biosimilar Abatacept (DRL_AB) vs Orencia in Healthy Men
NCT06126042Phase 1Recruiting
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (3 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Area under the serum concentration-time curve from time zero extrapolated to infinity at Day 85 and Maximum observed serum concentration at Day 85. Started Oct 2023; status: recruiting.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06126042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126042.